Please login to the form below

Not currently logged in


This page shows the latest ruxolitinib news and features for those working in and with pharma, biotech and healthcare.

Novartis’ canakinumab failed to improve survival in COVID-19 study

Novartis’ canakinumab failed to improve survival in COVID-19 study

Novartis is also still conducting a phase 3 trial of its JAK1/2 inhibitor Jakavi (ruxolitinib) in COVID-19, with preliminary results from this study expect by the end of the ... including a phase 3 trial of ruxolitinib,” said John Tsai, head of global

Latest news

More from news
Approximately 10 fully matching, plus 22 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...